Противовирусный препарат Кагоцел и новый коронавирус SARS-CoV-2 (COVID-19)

Kagocel wins the Smartpharma Awards for the third time

The antiviral drug "Kagocel" has again been recognized as No. 1 antiviral agent against influenza and ARVI for adults and children from 3 years of age. The drug wins in this category for the third year in a row.

The award ceremony of the prestigious Smartpharma Awards was held in Moscow at the Pravda Event Hall on April 15. The specific feature of the award is that the best drugs are selected by pharmacy specialists’ vote. This year, over 28,000 pharmacy employees were invited to participate in voting, with more than 50 pharmaceutical companies listed as nominees.

According to Arkady Ivanchenko, Head of the Marketing and Advertising Department of the Nearmedic Group of Companies, to participate in the competition together with other market leaders and receive recognition from the professional community during the pandemic is of special value. "In the past year, all other viral diseases took a back seat to the coronavirus. But that regards to the public perception only. In reality, people continue to suffer from influenza and ARVI, and are still in need of an effective remedy for prevention and treatment. It makes us happy that the confidence of the industry and consumers in Kagocel has only strengthened. After all, unlike other antiviral drugs, Kagocel protects patients from various respiratory viruses carefully and causes close to none side effects. In addition, interferon inducers, where Kagocel belongs, are consistently included in the constantly updated Provisional Guidelines for the prevention, diagnosis, and treatment of COVID-19 by the Ministry of Health of Russia. The effectiveness of such drugs in the fight against coronavirus infection has also been confirmed by recognized experts," Arkady Ivanchenko said.

22.04.2021 17:32:00

← Back to the list